DE69941051D1 - Expression und charakterisierung eines hiv-1 hüllproteins, das mit einer breitreaktiven neutralisier - Google Patents

Expression und charakterisierung eines hiv-1 hüllproteins, das mit einer breitreaktiven neutralisier

Info

Publication number
DE69941051D1
DE69941051D1 DE69941051T DE69941051T DE69941051D1 DE 69941051 D1 DE69941051 D1 DE 69941051D1 DE 69941051 T DE69941051 T DE 69941051T DE 69941051 T DE69941051 T DE 69941051T DE 69941051 D1 DE69941051 D1 DE 69941051D1
Authority
DE
Germany
Prior art keywords
hiv
neutralizes
characterization
expression
reactive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69941051T
Other languages
German (de)
English (en)
Inventor
Gerald Quinnan
Peng Fei Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henry M. Jackson Foundation
Original Assignee
Henry M. Jackson Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henry M. Jackson Foundation filed Critical Henry M. Jackson Foundation
Application granted granted Critical
Publication of DE69941051D1 publication Critical patent/DE69941051D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Plant Substances (AREA)
DE69941051T 1998-08-04 1999-08-04 Expression und charakterisierung eines hiv-1 hüllproteins, das mit einer breitreaktiven neutralisier Expired - Lifetime DE69941051D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9526798P 1998-08-04 1998-08-04
PCT/US1999/017596 WO2000007631A1 (en) 1998-08-04 1999-08-04 Expression and characterization of hiv-1 envelope protein associated with a broadly reactive neutralizing antibody response

Publications (1)

Publication Number Publication Date
DE69941051D1 true DE69941051D1 (de) 2009-08-13

Family

ID=22251048

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69941051T Expired - Lifetime DE69941051D1 (de) 1998-08-04 1999-08-04 Expression und charakterisierung eines hiv-1 hüllproteins, das mit einer breitreaktiven neutralisier

Country Status (7)

Country Link
EP (1) EP1104310B1 (cg-RX-API-DMAC7.html)
JP (1) JP4637356B2 (cg-RX-API-DMAC7.html)
AT (1) ATE435034T1 (cg-RX-API-DMAC7.html)
AU (1) AU762376C (cg-RX-API-DMAC7.html)
CA (1) CA2338886C (cg-RX-API-DMAC7.html)
DE (1) DE69941051D1 (cg-RX-API-DMAC7.html)
WO (1) WO2000007631A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW511388B (en) 2000-03-28 2002-11-21 Koninkl Philips Electronics Nv Passive radiator having mass elements
US20080057492A1 (en) * 2002-05-10 2008-03-06 Quinnan Jr Gerald V Interacting site for gp41 on gp120 of hiv-1
ES2385481T3 (es) * 2003-06-20 2012-07-25 Siemens Healthcare Diagnostics Products Gmbh Nueva variante de proteína de superficie (HbsAg) del virus de hepatitis B
US7485312B2 (en) 2003-06-20 2009-02-03 Dade Behring Marburg Gmbh Surface protein (HBsAg) variant of the hepatitis B virus
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
EP2013227A4 (en) * 2006-05-09 2010-07-28 Jackson H M Found Military Med HIV-1 immunostained compositions
CA2705373A1 (en) * 2007-11-12 2009-08-20 The Henry M. Jackson Foundation For The Advancement Of Military Medicine , Inc. Hiv-1 envelope glycoprotein oligomer and methods of use
MX2012011189A (es) 2010-03-26 2013-02-07 Glaxosmithkline Biolog Sa Vacuna contra el virus e inmunodeficiencia humana.
WO2012041842A1 (en) 2010-09-27 2012-04-05 Glaxosmithkline Biologicals S.A. Vaccine
EP2892554B1 (en) 2012-09-07 2020-08-26 Emory University Hiv immune stimulating compositions comprising recombinantly expressed pili on bacteria and methods related thereto

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5820865A (en) * 1988-01-26 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Method to induce cytotoxic T Lymphocytes specific for a broad array of HIV-1 isolates using hybrid synthetic peptides
GB8923123D0 (en) * 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
WO1992020373A1 (en) * 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
DE570357T1 (de) * 1992-05-14 1994-07-28 Polimun Scientific Immunbiologische Forschungsgesellschaft Mbh, Wien Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren.
GB9318901D0 (en) * 1993-09-13 1993-10-27 Centre Nat Rech Scient Multiple branch peptide construction

Also Published As

Publication number Publication date
AU762376C (en) 2004-10-14
EP1104310A4 (en) 2003-01-08
JP4637356B2 (ja) 2011-02-23
JP2002522039A (ja) 2002-07-23
AU5464299A (en) 2000-02-28
CA2338886A1 (en) 2000-02-17
EP1104310A1 (en) 2001-06-06
AU762376B2 (en) 2003-06-26
CA2338886C (en) 2011-10-04
WO2000007631A1 (en) 2000-02-17
WO2000007631A9 (en) 2000-11-16
EP1104310B1 (en) 2009-07-01
ATE435034T1 (de) 2009-07-15

Similar Documents

Publication Publication Date Title
NZ237666A (en) Hiv envelope (env) polypeptides, antibodies and compositions for treating aids
ATE64601T1 (de) Lymphadenopathie-assoziierte huellenantigene und deren verwendungen.
EA200200820A1 (ru) Пептиды, полученные из казеина, и их применение в терапии
PE20040554A1 (es) Vacunas que comprenden proteinas de fusion
DE69721713D1 (de) Humaner monoklonaler antikörper gegen hepatitis b virus oberflächen antigen (hbvsag)
CA2096159A1 (en) Peptides that induce antibodies which neutralize genetically divergent hiv-1 isolates
ATE238065T1 (de) Peptide zur verwendung in impfung und anregung von antikörperbildung gegen menschliches immunschwäche virus
DE60037450D1 (de) Funf-helix protein
ES2129487T3 (es) Peptidos sinteticos, anticuerpos dirigidos contra ellos y su utilizacion.
WO1999050301A3 (en) Epitopes in viral envelope proteins and specific antibodies directed against these epitopes: use for detection of hcv viral antigen in host tissue
DK1278534T3 (da) Fremgangsmåder og sammensætninger til svækkelse af multiplikationen af HIV-1
DE3855134D1 (de) Monoklonale menschliche antikörper gegen hiv-i
EA200401081A1 (ru) Fab-фрагменты моноклонального антитела человека, направленные против гликопротеина e2 hcv и обладающие нейтрализующей активностью in vitro
ATE280227T1 (de) Epitope von stress proteinen
ATE435034T1 (de) Expression und charakterisierung eines hiv-1 hüllproteins, das mit einer breitreaktiven neutralisierenden antikörperantwort assoziiert ist.
ATE130198T1 (de) Herstellung eines virus und reinigung von virenüberzugsproteinen zur impfstoffverwendung.
EP0602046A4 (en) DETECTING THE MAMMAL VIRUS WEAK VIRUS.
ATE285418T1 (de) Humanisierter antikörper spezifisch für das oberflächenantigen pre-s1 von hbv und dessen präparation
EP0725081A4 (en) MONOCLONAL ANTIBODY AGAINST MxA OF HUMAN Mx PROTEIN
CA2137280A1 (fr) Clonage du gene codant pour la proteine gp28.5 de toxoplasma gondii; fragments peptidiques de cette proteine et leurs applications
AU4948597A (en) Monoclonal antibodies against the ypydvpdya epitope, process for producing the same and their use
DE69840628D1 (de) Nicht-anaphylaktische allergenarten und ihre verwendung
ATE245661T1 (de) Natürliche menschliche igm antikörper
WO2000058438A3 (en) Conformationally constrained peptides
SE9600436D0 (sv) Vaccine against hantavirus

Legal Events

Date Code Title Description
8364 No opposition during term of opposition